Correspondence to: Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients

Allergy. 2022 Mar;77(3):1073-1074. doi: 10.1111/all.15185.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Alopecia Areata* / drug therapy
  • Antibodies, Monoclonal, Humanized / adverse effects
  • Dermatitis, Atopic*
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • dupilumab

Supplementary concepts

  • Diffuse alopecia